AstraZeneca

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.

AstraZeneca faced clotting concerns for Andexxa and discontinued a Phase II opioid use disorder trial, AZD4041, due to drug-drug interaction risks.

Amneal Pharmaceuticals resubmits NDA for DHE autoinjector after FDA rejection, aiming for first market approval. Expected FDA review completion in Q2 2025.

Cinclus Pharma reached an agreement with the FDA on its Pediatric Study Plan (iPSP), a prerequisite for market approval of linaprazan glurate for adult patients, and potential expanded approval for children.

The 'Lupus Nephritis - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current and future prospects of Lupus Nephritis treatments. It details the pipeline landscape, including disease overview, treatment guidelines, and assessments of emerging drugs like QLG1074, ADX-097, KYV-101, CABA-201, and NKX019. The report highlights ongoing R&D efforts, key collaborations, and trends in drug development, focusing on novel approaches to improve disease management. It also covers clinical trial stages, route of administration, and molecule types, identifying unmet needs and the impact of emerging therapies.

Aficamten treatment in FOREST-HCM trial showed 70% of SRT-eligible oHCM patients no longer needing SRT after 24 weeks, with 92.9% improving at least 1 NYHA class.

The article discusses the importance of enabling JavaScript for optimal app performance.

Conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, financial planning, and innovative technologies. Focuses on networking, case studies, presentations, and round tables.

FDA approves Jazz Pharmaceuticals' Ziihera (zanidatamab), the first dual HER2-targeted bispecific antibody for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, administered every two weeks.